KMT Hepatech, Inc. is a part of PhoenixBio group since December 1, 2017
KMT Hepatech provides efficient and cost-effective in vivo research services utilizing platform technology of small animal model, the PXB-Mouse®.
The PXB-Mouse® is a chimeric mouse model with humanized liver with stable human hepatocytes engraftment of over 70 per cent.
In addition to in vivo services, KMT Hepatech will expand operations and start production of PXB-Cells® - hepatocytes isolated from a PXB-Mouse® liver.
Due to the expanding interest in the humanized liver mouse model across a wide range of drug development fields, the company now offers services in the following areas:
- Infectious diseases, such as Hepatitis C, Hepatitis B and Malaria
- Safety toxicity: early assessment of potential hepatotoxicity in in vivo settings prior to first-in-human studies
- Characterization of human-type drug and lipoprotein metabolism in in vivo settings prior to first-in-human studies
KMT Hepatech, Inc. owns an international patent portfolio that includes coverage of the uPA chimeric mouse model of HCV infection and on the uPA chimeric mouse for all potential applications including HBV, malaria and studies of toxicity, drug and lipoprotein metabolism.
The PXB-Mouse® and PXB-Cells® are your essential tools for therapeutics and vaccine development.
December 21 2017
KMT will provide services with PXB-Mouse and produce PXB-Cells in its facility in Alberta, Canada
November 16 2017
KMT will become a subsidiary of PhoenixBio group and expand its operations
October 16 2017
Discuss with KMT Hepatech representative in Berlin, Germany on November 6-8